Literature DB >> 2253675

Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals.

D A Sica1, T J Comstock, J Davis, L Manning, R Powell, A Melikian, G Wright.   

Abstract

We determined plasma methocarbamol concentrations over 24 h following a 1.5 g methocarbamol dose (off-dialysis day) to 8 chronic haemodialysis patients and compared these results to those from 17 healthy male volunteers. The harmonic mean elimination half-life was similar between the two groups, 1.24 and 1.14 h, respectively. tmax and the weight-adjusted Cmax were 1.1 h and 27.0 mg.m-1 for haemodialysis patients and 1.1 and 23.1 mg.l-1 for normals. Relative systemic availability was assessed by comparing weight-normalized AUC x k10 products. These results indicate no significant differences with respect to methocarbamol absorption, with the relative systemic availability in patients being 113%. These data suggest that absorption and elimination of methocarbamol is similar between normal subjects and patients undergoing maintenance haemodialysis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253675     DOI: 10.1007/bf00280060

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  6 in total

1.  Metabolism of methocarbamol in the rat, dog, and human.

Authors:  R B Bruce; L B Turnbull; J H Newman
Journal:  J Pharm Sci       Date:  1971-01       Impact factor: 3.534

2.  Liver dysfunction in dialysis patients.

Authors:  A P Quintanilla
Journal:  Int J Artif Organs       Date:  1986-01       Impact factor: 1.595

Review 3.  Glucuronidation and disposition of drug glucuronides in patients with renal failure. A review.

Authors:  R K Verbeeck
Journal:  Drug Metab Dispos       Date:  1982 Jan-Feb       Impact factor: 3.922

Review 4.  Uremia and the liver. II. Drugs and the liver in the uremic patient.

Authors:  P Simon; A Meyrier; P Brissot
Journal:  Nephron       Date:  1981       Impact factor: 2.847

5.  Method of estimating relative absorption of a drug in a series of clinical studies in which blood levels are measured after single and/or multiple doses.

Authors:  J G Wagner
Journal:  J Pharm Sci       Date:  1967-05       Impact factor: 3.534

Review 6.  Renal disease and drug metabolism: an overview.

Authors:  T P Gibson
Journal:  Am J Kidney Dis       Date:  1986-07       Impact factor: 8.860

  6 in total
  1 in total

1.  A Randomized, Double-Blind, Placebo-Controlled Trial of Naproxen With or Without Orphenadrine or Methocarbamol for Acute Low Back Pain.

Authors:  Benjamin W Friedman; David Cisewski; Eddie Irizarry; Michelle Davitt; Clemencia Solorzano; Adam Nassery; Scott Pearlman; Deborah White; E John Gallagher
Journal:  Ann Emerg Med       Date:  2017-10-28       Impact factor: 5.721

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.